October 25, 2012 at 04:00 AM EDT
Out of the Red and into the Black: John McCamant on Investment in Blood Cancer Companies
The Life Sciences Report: I know you have great interest in cancer drug development. Do you see hematology/oncology (heme/onc) indications as areas of unmet need right now? John McCamant: Heme/onc has been an area . . . → Read More: Out of the Red and into the Black: John McCamant on Investment in Blood Cancer Companies

The Life Sciences Report: I know you have great interest in cancer drug development. Do you see hematology/oncology (heme/onc) indications as areas of unmet need right now?

John McCamant: Heme/onc has been an area of success for biotech companies. We have seen Celgene Corp. (CELG:NASDAQ) target multiple myeloma with Revlimid (lenalidomide), and we’ve seen other drugs in this space, such as Genentech/Roche Holding AG’s … [visit site to read more]

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here